Upcoming Conferences for argenx
argenx (Euronext & NASDAQ: ARGX), a prominent global leader in immunology, has exciting news to share. The company's management team is gearing up to participate in several significant investor conferences this December. These conferences present a unique opportunity for argenx to connect with investors and share insights about their groundbreaking work in the field of autoimmune diseases.
Featured Conferences
One of the highlights will be at Citi's 2024 Global Healthcare Conference, where argenx will partake in a fireside chat on Tuesday, December 3 at 1:45 p.m. ET. Shortly after, on December 4, they will feature once more at the 7th Annual Evercore I&I HealthCONx Conference, with another engaging fireside chat set for 1:45 p.m. ET.
The excitement continues on December 5 at Piper Sandler's 35th Annual Healthcare Conference, where the management team will support their thriving mission and present their innovative strategies at 9:00 a.m. ET in New York.
Focus on Autoimmune Diseases
As a company dedicated to enhancing the lives of those affected by severe autoimmune diseases, argenx is making strides through its unique Immunology Innovation Program (IIP). This initiative emphasizes collaboration with leading academic researchers to transition innovative immunology research into their portfolio of advanced antibody-based therapies.
Transformational Treatments
One of the cornerstones of argenx's therapeutic efforts is the development and commercialization of the first approved neonatal Fc receptor (FcRn) blocker. This transformative treatment is now available across various markets including the U.S., Japan, Israel, the EU, the UK, China, and Canada. The company is conducting ongoing evaluations of efgartigimod in several serious autoimmune conditions, which is pivotal in their goal to meet the urgent needs of patients worldwide.
Further Engagement with Investors
Investors interested in more details regarding argenx's involvement in these significant events can find comprehensive information on the investor relations section of the argenx website. This accessibility ensures that stakeholders stay informed about argenx’s innovations and future endeavors in immunology.
Commitment to Transparency
Transparency and engagement are key principles for argenx. The management team's participation in these conferences not only highlights their ambitious goals but also reinforces their commitment to keeping investors and the public well-informed about their progress and strategic vision.
Connecting with argenx
For those who want to keep in touch or learn more about the company’s innovations and news, argenx offers various channels including their website and social media platforms. Engaging with these resources allows for a deeper understanding of the impactful work being done by this groundbreaking company.
Contact Information
If you seek further information about argenx or have specific media inquiries, the company has designated contacts for ease of communication:
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy (US)
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
Frequently Asked Questions
What is the purpose of the conferences argenx is attending?
These conferences allow argenx to engage with investors and share updates on their work in immunology.
Who are the key speakers from argenx at these events?
The management team will represent argenx during the presentations and discussions at each conference.
What kind of treatments is argenx focused on?
argenx specializes in developing therapies for severe autoimmune diseases through innovative antibody-based medicines.
How can I stay updated with argenx's news?
Follow the companies on their official website and social media platforms for the latest updates.
Who can I contact for more information on argenx?
Media inquiries can be directed to Ben Petok, while investor inquiries can be handled by Alexandra Roy and Lynn Elton.
